Analysis of genotype–phenotype correlation in patients with α-thalassemia from Fujian province, Southeastern China

Yali Pan1,2 | Meihuan Chen1 | YanHong Zhang3 | Min Zhang1 | Lingji Chen1 | Na Lin1 | Liangpu Xu1 | Hailong Huang1,2

1Medical Genetic Diagnosis and Therapy Center of Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fujian Provincial Key Laboratory of Prenatal Diagnosis and Birth Defect, Fuzhou, China
2Medical Technology and Engineering College of Fujian Medical University, Fuzhou, China
3Fujian University of Traditional Chinese Medicine, Fuzhou, China

Correspondence
Na Lin, Liangpu Xu and Hailong Huang, Medical Genetic Diagnosis and Therapy Center of Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fujian Provincial Key Laboratory of Prenatal Diagnosis and Birth Defect, Fuzhou 350001, Fujian Province, China. Emails: 846519465@qq.com; xiliangpu@fjmu.edu.cn; huanghailong@fjmu.edu.cn

Abstract
Background: There is a high carrying rate of α-thalassemia in Fujian province. However, there are few large-scale studies on the correlation between genotype and phenotype in Fujian province. The purpose of this study was to analyze the phenotype and genotype in a cohort of 2923 patients with α-thalassemia in Fujian province, so as to provide reference data for screening and diagnosis of α-thalassemia in Fujian province.

Methods: The genotype of α-thalassemia was detected by PCR reverse dot blot assay, gap-PCR, single PCR, nested PCR, and sequencing. Clinical and hematological indices of 2923 patients were collected, and the correlation between genotype and phenotype was analyzed.

Results: Among 10,350 patients, 2923 cases were found with α-thalassemia, with a detection rate of 28.24%. Among them, --SEA/αα was the most common genotype, accounting for 64.80%. In addition, rare α-thalassemia genotypes were detected in Fujian province, including --THAI/αα (0.41%), HKαα/--SEA (0.03%), and the novel α-thalassemia gene mutation CD5 (GCC>ACC) (HGVS named HBA1: c.16G>A) (0.03%). Patients with deletional genotypes of α-thalassemia were found to have higher RBC and lower Hb, MCV, MCH, and HbA2 than patients with non-deletional genotypes of α-thalassemia (p < 0.05).

Conclusion: The clinical phenotype of α-thalassemia is influenced by molecular mechanisms. HBA1: c.16G>A mutation is a novel mutation that was first reported in Fujian province, which enriches the human hemoglobin mutation spectrum.

KEYWORDS
gene diagnosis, genotype, novel gene mutation, phenotype, α-thalassemia
1 | INTRODUCTION

α-thalassemia is one of the most common autosomal recessive genetic diseases in the world. Its pathogenesis is due to the defect of α-globin gene; the synthesis of α-globin peptide chain was partially or completely inhibited, resulting in hereditary hemolytic anemia. It is one of the most common monogenic diseases with the highest incidence in the world and has attracted extensive attention at home and abroad because of its fatal and disabling nature, which can lead to birth death or birth defects.1 Around 80%–90% of α-thalassemia is caused by genomic deletion of the α-globin gene cluster on chromosome 16p13.3.2 There is increasing evidence that around 7.0% of the world’s population are carriers of mutations in the α-globin gene.3 α-thalassemia has obvious regional or population differences and is mainly found in the Mediterranean, Africa, and Southeast Asia. The incidence of α-thalassemia is high in southern China, especially in Sichuan, Yunnan, Guangxi, Guizhou, Guangdong, and Fujian.4 Fujian province, located in the southeast coastal area of China, is a province with high incidence of α-thalassemia.5 At present, there is no other specific treatment for severe α-thalassemia except long-term blood transfusion or hematopoietic stem cell transplantation. Therefore, understanding the prevalence of α-thalassemia in high incidence areas, monitoring the population of childbearing age, preventing the birth of children with severe α-thalassemia, and gradually eliminating the prevalence of α-thalassemia in the population through genetic intervention are the only coping methods.

However, there are few large-scale studies on the correlation between genotype and phenotype in α-thalassemia patients in Chinese population. In this study, 10,350 patients from Fujian province were analyzed for genotype and phenotype. Such a study may provide more data for genetic counseling and clinical diagnosis in this region.

2 | METHODS

2.1 | Ethics statement

This study was reviewed and approved by the Ethics Review Committee of Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University. Signed informed consent was obtained from all participants following a detailed description of the purpose of the study. All experiments were performed in accordance with relevant guidelines and regulations.

2.2 | Subjects and hematological indicator detection

From January 2019 to November 2021, peripheral blood samples of patients who underwent thalassemia-related examinations in outpatients and inpatients of Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University were collected. A total of 10,350 patients (3407 males and 6943 females) with household registration in Fujian province were screened, including 2923 cases of α-thalassemia. α-thalassemia was confirmed by molecular analyses. Information about patients diagnosed with α-thalassemia was collected, and their genotypes and phenotypes were statistically analyzed. The median age was 27 (8.31) years. The median age was 5.5 (1.30) years for males and 28 (25.31) years for females. Exclusion criteria are as follows: (1) β-thalassemia; (2) other blood diseases such as iron deficiency anemia and megaloblastic anemia; (3) malignant tumor; (4) systemic immune disorders; and (5) allergic constitution. Peripheral blood samples were collected from selected subjects and anticoagulated with EDTA-K2. Approximately 2 ml of the anticoagulated blood sample was used for analysis of blood cell parameters on a Sysmex XN-2000 automatic hematology analyzer (Sysmex; Shanghai, China), and the hemoglobin components and levels were analyzed using an automated capillary electrophoresis system (CapillaryS 2, software version 6.2; Sebia, Paris, France). Serum ferritin (SF) concentration, as a measure of iron status, was determined by the chemiluminescent microparticle immunoassay (CMIA) (Abbott; ARCHITECT ci16200, USA).

2.3 | Common genotype test

DNA was extracted using the DNA Blood Extraction Kit (Yaneng Biosciences, Shenzhen, China). The deletions (−SEAP, −α3.7/), and −α1.2/ and the mutations (αCS, αQS, and αWS) of α-thalassemia were analyzed by PCR reverse dot blot assay using commercial kits (Yaneng Biosciences, Shenzhen, China) as described. The 17 common β-thalassemia was performed using PCR reverse dot blot assay with the thalassemia gene detection kit (Yaneng Biosciences, Shenzhen, China) following the manufacturer’s instructions.

2.4 | Rare genotype test

−THAI genotype was tested using gap polymerase chain reaction (gap-PCR), and HKαα genotype was tested by single PCR and nested PCR, as described previously.7,8 For suspected rare types of α-thalassemia, the full-length α1-globin genes and the full-length α2-globin genes were amplified using PCR assay and checked. The purified PCR products were subjected to direct sequencing with an ABI 3100 DNA Sequencer (Applied Biosystems; Foster City, CA, USA) as described.

2.5 | Statistical analysis

All data were entered into and managed using Microsoft Excel 2007 (Microsoft; Redmond, WA, USA). The data were analyzed using the Statistical Package for the Social Sciences (SPSS) version 25 (IBM Inc., Chicago, USA). Associations between hematological indices and
the variant genotypes were assessed by a nonparametric Kruskal-Wallis test, presented as median (95% confidence interval). The results with \( p < 0.05 \) were considered statistically significant.

3 | RESULTS

3.1 | Genotypes of common and rare types of \( \alpha \)-thalassemia

Among 10,350 patients, 2923 patients with \( \alpha \)-thalassemia mutation were detected, with a detection rate of 28.24%, including 2666 cases (91.21%) of \( \alpha \) deletional genotype, 181 cases (6.19%) of \( \alpha \) mutational genotype, 12 cases (0.41%) of \( \alpha \) deletion combined with mutation, and 64 cases (2.19%) of mixed deletional and mutational genotype. Among 2923 patients with \( \alpha \)-thalassemia mutation, the common genotype accounted for 96.00% of all genotypes, mainly including \(-SE^{A}\)/\( \alpha \alpha \) (64.80%), \(-a^{3.7}\)/\( \alpha \alpha \) (18.95%), \(-a^{4.2}\)/\( \alpha \alpha \) (4.96%), \( a^{QS}\)/\( \alpha \alpha \) (3.63%), \( a^{QS}\)/\( \alpha \alpha \) (1.47%), \(-SE^{A}\)/\( -a^{3.7}\) (1.20%), and \( a^{WS}\)/\( \alpha \alpha \) (0.99%). In addition, rare \( \alpha \)-thalassemia genotypes including \( .^{THAI}\)/\( \alpha \alpha \) (0.41%), \( HK\alpha\)/\( -SE^{A}\) (0.03), and the novel \( \alpha \)-thalassemia gene mutation \( CD5\) (GCC>ACC) (HGVS named \( HBA1\): c.16G>A) (0.03) were detected in Fujian province (Table 1).

3.2 | Hematological indices, the hemoglobin components and levels, and SF of patients with different genotypes of \( \alpha \)-thalassemia

Hematological indices, the hemoglobin components and levels, and SF were analyzed in this study, and we found that the red blood cell count (RBC) in patients with deletional genotypes of \( \alpha \)-thalassemia was higher than that in patients with non-deletional genotypes of \( \alpha \)-thalassemia (5.3 (5.0, 5.8) \times 10^{12}/L vs 4.9 (4.5, 5.4) \times 10^{12}/L) (\( p < 0.05 \)). Conversely, the levels of Hb, MCV, MCH, and HbA2 in patients with deletional genotypes of \( \alpha \)-thalassemia were lower than that in patients with non-deletional genotypes of \( \alpha \)-thalassemia (112.0 (106.0, 120.0) g/L vs 119.0 (111.0, 126.8) g/L, 67.5 (65.0, 69.5) fl vs 76.1 (72.2, 79.5) fl, 21.2 (20.5, 21.9) pg vs 24.7 (23.0, 26.1) pg, and 2.3 (2.2, 2.5) % vs 2.5 (2.4, 2.7) %) (\( p < 0.05 \)). (Table 2).

Moreover, some indices in different deletional genotypes of \( \alpha \)-thalassemia and non-deletional genotypes of \( \alpha \)-thalassemia were various. Among the deletional genotypes of \( \alpha \)-thalassemia, patients with \(-SE^{A}\)/\( \alpha \alpha \) were found to have higher RBC, HbF, and SF and lower Hb, MCV, MCH, and HbA2 than patients with \(-a^{3.7}\)/\( \alpha \alpha \) (\( p < 0.05 \)). What is more, patients with \(-SE^{A}\)/\( \alpha \alpha \) were found to have higher RBC and lower Hb, MCV, MCH, and HbA2 than patients with \(-a^{4.2}\)/\( \alpha \alpha \) (\( p < 0.05 \)). Age of \(-SE^{A}\)/\( \alpha \alpha \) was lower than that of \(-a^{3.7}\)/\( \alpha \alpha \) and \(-a^{4.2}\)/\( \alpha \alpha \) (\( p < 0.05 \)). Among the non-deletional genotypes of \( \alpha \)-thalassemia, patients with \( a^{QS}\)/\( \alpha \alpha \) were found to have higher RBC and HbA2 and lower MCV and MCH than patients with \( a^{QS}\)/\( \alpha \alpha \) (\( p < 0.05 \)). Patients with \( a^{QS}\)/\( \alpha \alpha \) were found to have lower MCV and MCH than patients with \( a^{WS}\)/\( \alpha \alpha \) (\( p < 0.05 \)). In addition, patients with \( a^{CS}\)/\( \alpha \alpha \) were found to have lower HbA2 than patients with \( a^{WS}\)/\( \alpha \alpha \) (\( p < 0.05 \)). (Table 2).

3.3 | Hematological analysis and molecular diagnosis of the novel \( \alpha \)-thalassemia gene mutation in Fujian province

In this study, we found a patient showed moderate microcytic hypochromic anemia with Hb 86 g/L, MCV 66.4 fL, and MCH 19.1 pg and decreased level of HbA2 (1.9%) that was suspected to be a \( \alpha \)-thalassemia carrier. Sequencing the full-length \( \alpha \)-globin gene and of the full-length \( \alpha \)-globin gene of the DNA from the peripheral blood sample was done. The results showed there were double peaks at nt224, G>A, in HBA1, corresponding to CD5 (GCC>ACC). It was named HBA1: c.16G>A using the Human Genome Variation Society (HGVS) nomenclature (Table 3, Figure 1).

4 | DISCUSSION

\( \alpha \)-thalassemia is common genetic diseases in human and is a specific recessive genetic disease caused by the obstruction of \( \alpha \)-globin peptide chain synthesis.\(^{10}\) The correlation between genotype and phenotype in 78 patients with \( \alpha \)-thalassemia in Hainan province was reported,\(^{11}\) and our previous study also reported the distribution of genotype in 314 patients with \( \alpha \)-thalassemia in Fujian province.\(^{12}\) In this study, we further analyzed the correlation between genotype and phenotype in a large sample of 2923 cases of \( \alpha \)-thalassemia in Fujian province, filling in the gap in this field.

There are two types of \( \alpha \)-thalassemia: deletional genotype and non-deletional genotype. In addition to the most common deletional genotype, rare deletional genotype of \( \alpha \)-thalassemia has been found in different populations.\(^{13}\) Up to now, more than 40 different deletional genotypes of \( \alpha \)-thalassemia have been described, of which 10 types have been found in China.\(^{14}\) There are three kinds of deletional genotype of \( \alpha \)-thalassemia in clinic: \(-SE^{A}\)/\( \alpha \alpha \), \(-a^{3.7}\)/\( \alpha \alpha \), and \(-a^{4.2}\)/\( \alpha \alpha \). Among 2923 cases with \( \alpha \)-thalassemia, there were 1894 cases (64.80%) with \(-SE^{A}\)/\( \alpha \alpha \), 554 cases (18.95%) with \(-a^{3.7}\)/\( \alpha \alpha \), and 145 cases (4.96%) with \(-a^{4.2}\)/\( \alpha \alpha \), suggesting that the most common genotype of \( \alpha \)-thalassemia in this region was \(-SE^{A}\)/\( \alpha \alpha \), which was consistent with the reports from Guangxi, Guangdong, Chongqing, and Hainan.\(^{15}\) The most common non-deletional genotypes of \( \alpha \)-thalassemia were \( a^{QS}\)/\( \alpha \alpha \) (3.63%), followed by \( a^{CS}\)/\( \alpha \alpha \) (1.47%) and \( a^{WS}\)/\( \alpha \alpha \) (0.99%), which were the same as those in Chongqing and slightly different from those in Guangxi, Guangdong, and Hainan.\(^{16-19}\) and were speculated to be related to regional population and other genetic factors. The spectrum of mutations detected in this study is similar to that observed in adjacent provinces, but there are differences in genotype prevalence in different regions. The incidence of \( \alpha \)-thalassemia in adjacent provinces of Fujian, such as Guangdong, Guangxi, and Jiangsu, was respectively 8.53%, 15.33%, and 1.48%.
**TABLE 1** Genotyping of α-thalassemia in Fujian province

| Genotype | Phenotype | No. patients detected | Constituent ratio (%) |
|----------|-----------|-----------------------|-----------------------|
| **Common α-thalassemia** | | | |
| \(\text{\_SEA/\text{\_ax}}\) | \(\alpha^{0}/\alpha\) | 1894 | 64.80 |
| \(\alpha^{3.7}/\text{\_ax}\) | \(\alpha^{2}/\alpha\) | 554 | 18.95 |
| \(\alpha^{4.2}/\text{\_ax}\) | \(\alpha^{2}/\alpha\) | 145 | 4.96 |
| \(\text{\_SEA}/\alpha^{3.7}\) | \(\alpha^{0}/\alpha^{+}\) | 35 | 1.20 |
| \(\text{\_SEA}/\alpha^{4.2}\) | \(\alpha^{0}/\alpha^{+}\) | 12 | 0.41 |
| \(\alpha^{3.7}/\alpha^{4.2}\) | \(\alpha^{2}/\alpha^{+}\) | 2 | 0.07 |
| \(\alpha^{2.7}/\alpha^{4.2}\) | \(\alpha^{2}/\alpha^{+}\) | 11 | 0.38 |
| \(\alpha^{0}/\text{\_axax}\) | \(\alpha^{2}/\alpha\) | 106 | 3.63 |
| \(\alpha^{0}/\text{\_axax}\) | \(\alpha^{2}/\alpha\) | 43 | 1.47 |
| \(\alpha^{0}/\text{\_axax}\) | \(\alpha^{2}/\alpha\) | 29 | 0.99 |
| \(\alpha^{0}/\text{\_axax}\) | \(\alpha^{2}/\alpha\) | 1 | 0.03 |
| \(\alpha^{0}/\text{\_axax}\) | \(\alpha^{2}/\alpha\) | 1 | 0.03 |
| \(\alpha^{0}/\text{\_axax}\) | \(\alpha^{2}/\alpha\) | 2 | 0.07 |
| \(\alpha^{0}/\text{\_axax}\) | \(\alpha^{2}/\alpha\) | 2 | 0.07 |
| \(\alpha^{0}/\text{\_axax}\) | \(\alpha^{2}/\alpha\) | 4 | 0.14 |
| \(\alpha^{0}/\text{\_axax}\) | \(\alpha^{2}/\alpha\) | 1 | 0.03 |
| \(\alpha^{0}/\text{\_axax}\) | \(\alpha^{2}/\alpha\) | 2 | 0.07 |
| **Subtotal** | | | 2845 |
| **Rare α-thalassemia** | | | |
| \(\text{\_THAI/\text{\_ax}}\) | \(\alpha^{0}/\alpha\) | 12 | 0.41 |
| \(\text{\_axax/\text{\_SEA}}\) | \(\alpha^{2}/\alpha^{0}\) | 1 | 0.03 |
| \(\text{\_axax/GC}\) | \(\alpha^{2}/\alpha\) | 1 | 0.03 |
| **Subtotal** | | | 14 |
| **Common concurrent α-and β-thalassemia** | | | |
| \(\alpha^{3.7}/\text{\_ax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 4 | 0.14 |
| \(\text{\_SEA/\text{\_ax/\text{\_CD41-42(TCTT)/\beta^{N}}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 11 | 0.38 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 1 | 0.03 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 1 | 0.03 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 11 | 0.38 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 1 | 0.03 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 1 | 0.03 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 3 | 0.10 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 4 | 0.14 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 11 | 0.38 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 1 | 0.03 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 3 | 0.10 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 1 | 0.03 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 2 | 0.07 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 2 | 0.07 |
| \(\alpha^{0}/\text{\_axax/\text{\_CD41-42(TCTT)/\beta^{N}}}\) | \(\alpha^{2}/\alpha^{0}/\beta^{N}\) | 1 | 0.03 |
| **Subtotal** | | | 64 |
| **Total** | | | 2923 |

Note: \(\alpha^{0}\) indicates absent synthesis of \(\alpha\)-globin peptide chain; \(\alpha^{+}\) indicates reduced synthesis of \(\alpha\)-globin peptide chain; \(\alpha\) indicates no mutation. \(\beta^{0}\) indicates absent synthesis of \(\beta\)-globin peptide chain; \(\beta^{+}\) indicates reduced synthesis of \(\beta\)-globin peptide chain; \(\beta\) indicates no mutation.

Abbreviations: CS, Hb Constant Spring; HK, Hong Kong deletion; QS, Hb Quong Sze; SEA, Southeast Asian deletion; THAI, Thailand deletion; WS, Hb Westmead.
TABLE 2 Comparison of hematological indices between three common deletional genotypes and three common non-deletional genotypes of α-thalassemia patients

| Genotype | No. | Gender (F/M) | Age (year) | RBC (x10¹²/L) | Hb (g/L) | MCV (fl) | MCH (pg) | HbA2 (%) | HbF (%) | SF (μg/L) |
|----------|-----|--------------|------------|---------------|----------|---------|---------|----------|---------|-----------|
| Deletional genotype | 2593 | 1839/754 | 27.0 (5.0, 31.0) | 5.3 (5.0, 5.8) | 112.0 (106.0, 120.0) | 67.5 (65.0, 69.5) | 21.2 (20.5, 21.9) | 2.3 (2.2, 2.5) | 0.6 (0.2, 0.9) | 47.6 (25.0, 89.5) |
| -SEA/αα | 1894 | 1312/582 | 27.0 (22.0, 31.0) | 5.2 (4.9, 5.7) | 112.0 (105.0, 122.3) | 68.4 (66.6, 69.9) | 21.7 (21.0, 22.3) | 2.3 (2.2, 2.4) | 0.3 (0.1, 0.5) | 55.6 (33.5, 103.6) |
| -α-3.7/αα | 554 | 414/140 | 28.0 (25.0, 32.0) | 4.4 (4.0, 4.8) | 115.5 (107.5, 126.3) | 81.6 (79.8, 83.5) | 26.8 (26.1, 27.6) | 2.5 (2.4, 2.6) | 0.2 (0.1, 0.4) | 35.3 (13.1, 68.7) |
| -α-4.2/αα | 145 | 113/32 | 28.0 (25.0, 32.0) | 4.4 (4.2, 4.8) | 116.0 (106.0, 125.0) | 80.8 (78.4, 81.4) | 26.2 (25.5, 27.2) | 2.5 (2.3, 2.6) | 0.4 (0.1, 0.6) | 47.8 (18.6, 114.2) |
| Non-deletional genotype | 178 | 130/48 | 29.0 (24.0, 32.0) | 4.9 (4.5, 5.4) | 119.0 (111.0, 126.8) | 76.1 (72.2, 79.5) | 24.7 (23.0, 26.1) | 2.5 (2.4, 2.7) | 0.3 (0.1, 0.6) | 34.4 (13.8, 59.5) |
| αQS/αα | 106 | 75/31 | 28.0 (3.0, 32.0) | 4.7 (4.4, 5.0) | 114.0 (106.8, 121.0) | 76.0 (75.0, 77.9) | 24.3 (23.6, 25.0) | 2.6 (2.5, 3.0) | 0.2 (0.1, 0.4) | 31.8 (16.6, 40.7) |
| αCS/αα | 43 | 34/9 | 27.0 (25.5, 31.0) | 4.7 (4.3, 5.0) | 118.0 (112.0, 127.5) | 79.8 (76.8, 81.5) | 26.1 (24.6, 27.5) | 2.2 (2.1, 2.3) | 0.3 (0.1, 0.4) | 84.2 (16.5, 234.7) |
| αWS/αα | 29 | 21/8 | 28.5 (25.5, 30.0) | 4.5 (4.3, 5.0) | 119.0 (104.5, 126.0) | 80.3 (71.6, 81.0) | 26.3 (22.3, 27.3) | 2.7 (2.5, 3.0) | 0.2 (0.1, 0.4) | 22.3 (8.8, 57.2) |

A comparison of deletional genotype

| p-value | p-value | p-value |
|---------|---------|---------|
| <0.001* | <0.001* | <0.001* |
| 0.002* | <0.001* | <0.001* |
| 0.567 | 0.523 | 0.603 |

A comparison of non-deletional genotype

| p-value | p-value | p-value |
|---------|---------|---------|
| 0.704 | 0.045* | 0.949 |
| 0.510 | 0.250 | 0.671 |
| 0.606 | 0.952 | 0.444 |

A comparison of deletional genotype and non-deletional genotype

| p-value | p-value | p-value |
|---------|---------|---------|
| 0.509 | <0.001* | <0.001* |
| 0.001* | <0.001* | <0.001* |
| 0.042 | <0.001* | 0.191 |

Abbreviations: F, Female; M, Male.

*Subjects with -SEA/αα compared with were subjects with -α-3.7/αα.

bSubjects with -SEA/αα compared with were subjects with -α-4.2/αα.

cSubjects with -α-3.7/αα compared with were subjects with -α-4.2/αα.

dSubjects with αQS/αα compared with were subjects with αCS/αα.

eSubjects with αQS/αα compared with were subjects with αWS/αα.

fSubjects with αCS/αα compared with were subjects with αWS/αα.

gSubjects with deletional genotype compared with were subjects with non-deletional genotype.

hAll hematological indices with more than one records are presented as median (95% confidence interval). Bootstrap method is used in computing 95% confidence intervals.

*p < 0.05, Kruskal–Wallis test.
and \( -^{\text{SEA}}/\alpha\alpha \) was dominant in these provinces, and the frequencies were respectively 57.55%, 52.78%, and 83.87%. This is due to the random distribution of \( \alpha \)-thalassemia in the world, different ethnic regions have their own distribution characteristics. It is generally believed that populations with the same genetic background are prone to homogenous mutations.

Three rare \( \alpha \)-thalassemia genotypes were also detected in this study, including \( -^{\text{THAI}}/\alpha\alpha \) (12 cases, 0.41%), \( \text{HK}\alpha\alpha/-^{\text{SEA}} \) (1 case, 0.03%), and the novel \( \alpha \)-thalassemia gene mutation CD5 (GCC \( \rightarrow \) ACC) (1 case, 0.03%) in Fujian Province. \( -^{\text{THAI}} \) genotype has been gradually found in the population of southern China, mainly distributed in Guangxi, Guangdong, Taiwan, and Fujian. Like the \( -^{\text{SEA}} \) genotype, the phenotype of \( -^{\text{THAI}} \) is manifested as microcytic hypochromic anemia and the Thai-type homozygote or Thai-type heterozygotes with SEA-type \( \alpha \)-thalassemia are manifested as Bart’s hydrops fetalis. Because, testing for Thai-type gene mutation is not routinely performed, which often results in missed diagnosis. Up to now, there are few reports about HK\(\alpha\alpha/\alpha\alpha \) type thalassemia, which mainly occurs in Guangxi and Guangdong of China. HK\(\alpha\alpha \) allele is a special structure containing \( -\alpha^{3.7} \) fragment and \( \alpha\alpha\alpha^{264} \) fragment formed by recombination and unequal transposition of the homologous X segment of the \( \alpha \)-globin gene cluster. So far, \( \alpha\alpha\alpha^{264} \) fragments cannot be detected through the routine thalassemia diagnostic kit. The genotype of \( -\alpha^{3.7}/\alpha\alpha \), HK\(\alpha\alpha/-\alpha^{3.7} \), and HK\(\alpha\alpha/\alpha\alpha \) is entirely the result of \( -\alpha^{3.7}/\alpha\alpha \) by gap-PCR. The clinical symptoms of HK\(\alpha\alpha/\alpha\alpha \) were much milder than those of \( -\alpha^{3.7}/\alpha\alpha \). Therefore, the symptoms of thalassemia associated with HK\(\alpha\alpha/\alpha\alpha \) and \( -^{\text{SEA}} \) were milder than those of hemoglobin H disease associated with \( -\alpha^{3.7} \) and \( -^{\text{SEA}} \), and only mild globin production disorder was observed (usually Hb \( > 100 \) g/L). If both husband and wife carry HK\(\alpha\alpha/\alpha\alpha \) and \( -^{\text{SEA}} \), respectively, the fetus can be kept. However, if the HK\(\alpha\alpha/\alpha\alpha \) or \( -^{\text{THAI}} \) genotypes are incorrectly identified as \( -\alpha^{3.7}/\alpha\alpha \), it may lead to incorrect clinical treatment.

HBA1: c.16G\( \rightarrow \)A mutation was first reported in Fujian Province, which was discovered in Shenzhen. In their report, the phenotype of this mutation was normal and only with the decreased level of HbA2, considered as the polymorphism site of HBA1. However, in our study, the patient with this mutation showed moderate anemia symptoms, with Hb 86 g/L, MCV 66.4 fl, MCH 19.1 pg, and HbA2 1.9%, which might be due to the fact that the patient, who was pregnant, might show blood volume change and the patient was found to be diagnosed as iron deficiency anemia few days later, when follow-up.

In addition, 64 cases (2.19%) with concurrent \( \alpha \) - and \( \beta \)-thalassemia were detected in 2923 positive samples. Patients with concurrent \( \alpha \) - and \( \beta \)-thalassemia have been reported to suffer from mild anemia due to a reduction in \( \alpha \) - and \( \beta \)-globin chain synthesis, which alleviates the imbalance caused by reduced globin chain synthesis and thus reduces the severity of anemia. In this study, we detected 2.19% concurrent \( \alpha \) - and \( \beta \)-thalassemia, the five most common genotypes including \( -^{\text{SEA}}/\alpha\alpha/\beta^{IVS-2-654(C\rightarrow T)/\beta^N} \) (11 cases),...
α^3.7/αα/β^αα /N (11 cases), α^−SEA/αα/β^CD41-42I/CTTT //N (11 cases), α^−SEA/αα/β^CD41-42I/CTTT //N (4 cases), and α^−SEA/αα/β^A−G /β^N (4 cases). While patients with α- and β-thalassemia have milder symptoms, their offspring are more likely than the general population to develop severe thalassemia, and the long-term damage is much greater. Therefore, the clinical diagnosis of concurrent α- and β-thalassemia should not be ignored. According to Xiong Fu et al., concurrent α- and β-thalassemia is generally manifested as the phenotypic characteristics of β-thalassemia in Hb analysis, so α-thalassemia is easy to be missed and misdiagnosed in clinical diagnosis, which should be paid attention to.

There is significant variation in clinical severity among patients with α-thalassemia, which is indirectly reflected by the span of age at first diagnosis. Age of SEA / is easy to be missed and misdiagnosed in clinical diagnosis. Genotype of αα is more severe than in the deletional genotype. Patients with αα were associated with more severe anemia and came to the hospital earlier for diagnosis and treatment. Chen Suqin et al. demonstrated that factors such as age influenced the genotype and phenotype of α-thalassemia. Liebhaber et al. found that the α1-globin gene on the same chromosome as the Hb C5 mutation was only half as expressed as the α^−G2 or α^3.7 variants. Thus, the absence of α-globin peptide chains or the relative excess of β-globin peptide chains is more severe in non-deletional patients. The hematologic appearance of patients with non-deletional genotype of α-thalassemia differs from that patients with deletional genotype of α-thalassemia; anemia is more severe in non-deletional patients with non-deletional genotype of α-thalassemia. In our study, patients with deletional genotypes of α-thalassemia were found to have higher RBC and lower Hb, MCV, MCH, and HbA2 than patients with non-deletional genotypes of α-thalassemia (p < 0.05). It may be related to the damage of erythrocyte membrane caused by excess β-chain oxidation and αCSα or αCSα chain oxidation. This results in decreased EPO production and RBC in non-deletional genotypes of α-thalassemia. 35 α-thalassemia mainly affects the synthesis of Hb, which is the main content of red blood cells. Therefore, Hb, MCV, and MCH will show obvious changes. Interestingly, we found that αCSα/αα's Hb was lower than α^−CSα/αα and α^−G2/αα, which was partly supported that anemia in the non-deletional genotype was more severe than in the deletional genotype. Patients with αCSα/αα were found to have higher RBC, HbF, and SF, it may be related to αCSα/αα was associated with more γ-globin mutations, and its RBC synthesis requires more iron, so the RBC, HbF, and SF were higher than α^−CSα/αα. 36 The Hb, HbA2, MCV, and MCH of αCSα/αα were lower than α^−CSα/αα and α^−G2/αα in the three common deletional genotypes, suggesting that the severity of anemia depends on the number of inactivated α-globin genes.

In conclusion, the clinical manifestations and hematologic phenotypes of α-thalassemia are related to genotype. The clinical phenotype of α-thalassemia is influenced by molecular mechanisms. HBA1: c.16G>A is a novel mutation that was first reported in Fujian province. The discovery of this novel mutation in α-globin gene has enriched the database of hemoglobin variants, and the detailed genetic analysis and clinical symptom description of this mutation will contribute to further study of hemoglobin function in the future.

AUTHOR CONTRIBUTIONS
Yali Pan, Meihuan Chen, Na Lin, Liangpu Xu, and Hailong Huang designed and prepared the study. YanHong Zhang, Min Zhang, and Lingji Chen collected the literature and the data and prepared the study. All authors approved the final study.

ACKNOWLEDGMENTS
The authors also thank all patients for participating in this study.

FUNDING INFORMATION
This work was funded by the National Natural Science Foundation of China (no.81970170), the National Natural Science Foundation of Fujian Province (no.2019J01510), and the Fujian provincial health technology project (no.2018-1-21).

CONFLICT OF INTEREST
The authors confirm that they have no competing interests.

DATA AVAILABILITY STATEMENT
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

ORCID
Yali Pan https://orcid.org/0000-0002-8083-3541
Meihuan Chen https://orcid.org/0000-0002-7356-8751
Min Zhang https://orcid.org/0000-0003-1027-7196
Hailong Huang https://orcid.org/0000-0003-2924-399X

REFERENCES
1. Li CK. New trend in the epidemiology of thalassaemia. Best Pract Res Clin Obstet Gynaecol. 2017;39:16-26.
2. Farashi S, Harteveld CL. Molecular basis of α-thalassemia. Blood Cells Mol Dis. 2018;70:43-53.
3. Weatherall DJ. Thalassemia as a global health problem: recent progress toward its control in the developing countries. Ann N Y Acad Sci. 2010;1202:17-23.
4. Wang YY, Li XH, Xu XH. Progress in diagnosis and treatment of thalassemia and current situation in China. Chin J Med Genet. 2010;28(6):473-476.
5. XU L, HUANG H, WANG Y, et al. Molecular epidemiology of thalassemia in Fujian province. Chin J Med Genet. 2013:30(4):403-406.
6. XU C, LIAO B, QI Y, HUANGFU Z, CHEN J, CHEN Y. Analysis of gene mutation types of α- and β-thalassemia in Fuzhou, Fujian Province in China. Hemoglobin. 2018;42(3):143-147.
7. HUANG H, LIN N, XU L, et al. Prenatal diagnosis of Bart's hydrops fetalis due to Thailand-type of α-thalassemia.Chin. J Obstet Gynecol. 2010;7:531-533.
8. HUANG H, LIN N, LI Y, et al. Prenatal diagnosis of a rare case of HKαα combined with Southeast Asian deletion α-thalassemia.Chin. J Perinat Med. 2014;17(7):488-490.
9. HUANG H, XU L, CHEN M, et al. Molecular characterization of thalassemia and hemoglobinopathy in southeastern China. Sci Rep. 2019;9(1):3493.
10. Munkongdee T, Chen P, Winichagoon P, Fucharoen S, Paiboonsukwong K. Update in laboratory diagnosis of thalassemia. Front Mol Biosci. 2020;7:74.

11. Wu J, Lin L, Qin X. Genotype and hematological phenotype analysis of 78 α-thalassemia patients in Hainan. J Hainan Med Univ. 2012;18(11):1658-1661.

12. Xu L, Huang H, He D, et al. Analysis of α-Thalassemia Gene Mutations and Prenatal Diagnosis in Fujian Area. J Pract Obstet Gynecol. 2011;27(11):860-863.

13. Huang H, Lin Y, Lin N, et al. Spectrum of α-thalassemia mutations in Fujian province of South China. Int J Clin Exp Med. 2018;11(11):12488-12493.

14. Huang H, Chen M, Chen X, et al. A rare α-thalassemia deletion, -α27.6, is identified from three Chinese families in Fujian province. Int. J Clin Pathol. 2018;11(8):4012-4018.

15. Qiu Y, Zhao J. Progress of the risk prevention and control system for thalassemia at home and abroad. Chin J Fam Plan. 2019;27(2):264-268.

16. Long J. Condition of carrying alpha-thalassemia gene and investigation of detection range for hotspot mutation in population from southern region of Guangxi. Guangxi Med J. 2020;42(4):457-460.

17. Liu Y, Lin XY, Huang Y, et al. Values of MCV, MCH, ROFT and HbA2 for screening α-Thalassemia in Guangdong Area. J Exp Hematol. 2020;28(5):1679-1682.

18. Wu SS, Jiang F, Xiang GM, et al. Gene analysis of 2850 patients with thalassemia in Chongqing area. Chongqing Med J 2019;48(3):456-459+465.

19. Zhang JY, Li XJ, Fu SM. Analysis of gene mutation spectrum of thalassemia patients in Hainan. Hainan Med J. 2016;27(8):1228-1230.

20. Yang Y, Zhang J. Research progress on thalassemia in Southern China. J Exp Hematol. 2017;25(1):276-280.

21. Zheng CG, Liu M, Du J, et al. Molecular spectrum of α- and β-globin gene mutations detected in the population of Guangxi Zhuang Autonomous Region, People’s Republic of China. Hemoglobin. 2011;35(1):28-39.

22. Xu XM, Zhou YQ, Luo GX, et al. The prevalence and spectrum of alpha and beta thalassaemia in Guangdong Province: implications for the future health burden and population dynamics. J Clin Pathol. 2004;57(5):517-522.

23. Higgs DR, Ayyub H, Chong SS. The --THAI and --FIL determinants of alpha thalassemia in Taiwan. Am J Hematol. 1999;60(1):80-81.

24. Lin N, Huang H, Wang Y, et al. Analysis of prenatal gene diagnosis results of the 269 couples with the same type of thalassemia in Fujian province. Chin J Fam Plan. 2016;24(6):395-398.

25. Li DZ, Li Y, Li J, Li SC, Li R. Prevention of Hb Bart’s (y4) disease associated with the (- (THAI) α0)-thalassemia deletion in Mainland China. Hemoglobin. 2015;39(6):412-414.

26. Zhang M, Huang H, Chen M, et al. Frequencies and hematological manifestations of the Hκα allele in southern Chinese population. Int J Clin Exp Pathol. 2019;12(8):3058-3062.

27. Wu MY, Li J, Li SC, Li Y, Li DZ. Frequencies of Hκα and anti-Hκα alleles in Chinese carriers of silent deletional α-thalassemia. Hemoglobin. 2015;39(6):407-411.

28. Liu LY, Han LH, Li W, et al. Analysis of gene test results of 2898 thalassemia cases in Nanshan district of Shenzhen. Mod Prev Med. 2019;46(8):1528-1532.

29. Yu HS. Comparative analysis of different detection methods for serum ferritin. Guide Chin Med. 2020;18(29):50-51.

30. Guvec B, Canataroglu A, Unsal C, et al. β-Globin chain abnormalities with coexisting α-thalassemia mutations. Arch Med Sci. 2012;8(4):644-649.

31. Xiong F, Lou JW, Wei XF, et al. Analysis of hematological characteristics of 79 patients with β-thalassemia combined with α-thalassemia in Guangxi region. Chin J Hematol. 2012;33(10):856-860.

32. Chen SQ, Jiang WY, Chen LM, et al. Genotype-phenotype correlations of hemoglobin H disease in Southern China. New Chin Med. 2015;46(5):294-298.

33. Liebhaber SA, Cash FE, Main DM. Compensatory increase in alpha1-globin gene expression in individuals heterozygous for the alpha-thalassemia-2 deletion. J Clin Invest. 1985;76(3):1057-1064.

34. Chao YH, Wu KH, Wu HP, Liu SC, Peng CT, Lee MS. Clinical features and molecular analysis of HbH disease in Taiwan. Biomed Res Int. 2014;2014:271070.

35. Sriiam S, Leecharoenkiat A, Lithanatudom P, et al. Proteomic analysis of hemoglobin H-constant spring (Hb H-CS) erythroblasts. Blood Cells Mol Dis. 2012;48(2):77-85.

36. Li YY, Chen P, Xiao X, et al. Study on Aγ-196C→T mutation inducing nondeletional hereditary persistence of fetal hemoglobin. J Guangxi Med Univ. 2016;33(2):254-258.

How to cite this article: Pan Y, Chen M, Zhang Y, et al. Analysis of genotype-phenotype correlation in patients with α-thalassemia from Fujian province, Southeastern China. J Clin Lab Anal. 2022;36:e24696. doi: 10.1002/jcla.24696